JP2013531006A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013531006A5 JP2013531006A5 JP2013517611A JP2013517611A JP2013531006A5 JP 2013531006 A5 JP2013531006 A5 JP 2013531006A5 JP 2013517611 A JP2013517611 A JP 2013517611A JP 2013517611 A JP2013517611 A JP 2013517611A JP 2013531006 A5 JP2013531006 A5 JP 2013531006A5
- Authority
- JP
- Japan
- Prior art keywords
- depression
- disorder
- alkyl
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36250510P | 2010-07-08 | 2010-07-08 | |
| US61/362,505 | 2010-07-08 | ||
| PCT/IB2011/052686 WO2012004698A1 (en) | 2010-07-08 | 2011-06-20 | Piperidinyl pyrimidine amides as kv7 potassium channel openers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013531006A JP2013531006A (ja) | 2013-08-01 |
| JP2013531006A5 true JP2013531006A5 (https=) | 2014-06-05 |
| JP5763758B2 JP5763758B2 (ja) | 2015-08-12 |
Family
ID=44487037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013517611A Expired - Fee Related JP5763758B2 (ja) | 2010-07-08 | 2011-06-20 | Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8883812B2 (https=) |
| EP (1) | EP2590961A1 (https=) |
| JP (1) | JP5763758B2 (https=) |
| KR (1) | KR101449348B1 (https=) |
| CN (1) | CN102971307A (https=) |
| AU (1) | AU2011275393B2 (https=) |
| CA (1) | CA2804165C (https=) |
| MX (1) | MX2013000138A (https=) |
| SG (1) | SG186409A1 (https=) |
| WO (1) | WO2012004698A1 (https=) |
| ZA (1) | ZA201300499B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013067591A1 (en) * | 2011-11-10 | 2013-05-16 | Relevare Australia Pty Ltd | Topical formulations for pain management |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| WO2014145852A2 (en) | 2013-03-15 | 2014-09-18 | Knopp Biosciences Llc | Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators |
| SMT202300362T1 (it) * | 2014-09-12 | 2023-11-13 | Biohaven Therapeutics Ltd | Benzoimidazol-1,2-il-ammidi come attivatori di canale kv7 |
| EP4241843B1 (en) * | 2018-02-20 | 2025-05-21 | H. Lundbeck A/S | Alcohol derivatives as kv7 potassium channel openers |
| SG11202008030WA (en) | 2018-03-19 | 2020-10-29 | Knopp Biosciences Llc | Kv7 channel activators compositions and methods of use |
| AR119521A1 (es) * | 2019-08-02 | 2021-12-22 | H Lundbeck As | DERIVADOS DE ALCOHOL COMO ABRIDORES DEL CANAL DE POTASIO Kv7 |
| BR112022004847A2 (pt) * | 2019-09-17 | 2022-06-07 | Knopp Biosciences Llc | Método para tratar uma doença ou distúrbio de neurodesenvolvimento |
| WO2021119018A1 (en) * | 2019-12-09 | 2021-06-17 | The Board Of Trustees Of The Leland Stanford Junior University | A method to improve sleep quality in the elderly by controlling excitability of hypocretin neurons |
| WO2021211867A1 (en) * | 2020-04-16 | 2021-10-21 | Attune Neurosciences, Inc. | Kv7 modulators for treating sleep or anxiety disorders |
| BR112023003624A2 (pt) * | 2020-08-28 | 2023-03-28 | Pfizer | Ferramenta de suporte à decisão computadorizada e dispositivo médico para monitoramento e cuidado de condição respiratória |
| GB202306914D0 (en) * | 2023-05-10 | 2023-06-21 | Sania Rx Ltd | Method |
| CN119661413B (zh) * | 2024-12-28 | 2025-06-24 | 齐鲁医药学院 | Kv7钾离子通道开放剂及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20032233A3 (cs) * | 2001-02-20 | 2004-12-15 | Bristol-Myers Squibb Company | Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ |
| TWI349666B (en) | 2004-03-12 | 2011-10-01 | Lundbeck & Co As H | Substituted morpholine and thiomorpholine derivatives |
| US7091202B2 (en) * | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
| US20080261918A1 (en) | 2004-12-17 | 2008-10-23 | Graham Andrew Showell | Silicon Compounds and Their Use |
| US7322249B2 (en) | 2005-07-07 | 2008-01-29 | Delphi Technologies, Inc. | Mounting for a probe sensor |
| US7683058B2 (en) * | 2005-09-09 | 2010-03-23 | H. Lundbeck A/S | Substituted pyrimidine derivatives |
| KR20080043314A (ko) * | 2005-09-09 | 2008-05-16 | 하. 룬트벡 아크티에 셀스카브 | 피리미딘 유도체 및 ｋｃｎｑ 포타슘 채널 개방제로서의그의 용도 |
| TWI453013B (zh) | 2006-02-07 | 2014-09-21 | Lundbeck & Co As H | N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品 |
| SG174095A1 (en) * | 2006-08-23 | 2011-09-29 | Valeant Pharmaceuticals Int | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| US8367684B2 (en) * | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
| AR070513A1 (es) | 2007-08-01 | 2010-04-14 | Lundbeck & Co As H | Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor |
-
2011
- 2011-06-20 AU AU2011275393A patent/AU2011275393B2/en not_active Ceased
- 2011-06-20 CN CN2011800337518A patent/CN102971307A/zh active Pending
- 2011-06-20 EP EP11738482.6A patent/EP2590961A1/en not_active Withdrawn
- 2011-06-20 KR KR1020137000377A patent/KR101449348B1/ko not_active Expired - Fee Related
- 2011-06-20 CA CA2804165A patent/CA2804165C/en not_active Expired - Fee Related
- 2011-06-20 JP JP2013517611A patent/JP5763758B2/ja not_active Expired - Fee Related
- 2011-06-20 SG SG2012093761A patent/SG186409A1/en unknown
- 2011-06-20 US US13/808,355 patent/US8883812B2/en not_active Expired - Fee Related
- 2011-06-20 MX MX2013000138A patent/MX2013000138A/es active IP Right Grant
- 2011-06-20 WO PCT/IB2011/052686 patent/WO2012004698A1/en not_active Ceased
-
2013
- 2013-01-18 ZA ZA2013/00499A patent/ZA201300499B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013531006A5 (https=) | ||
| US11224573B2 (en) | Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor | |
| JP2017513942A (ja) | Ｍｅｒｔｋ特異的ピロロピリミジン化合物 | |
| AU2022298639C1 (en) | Diacylglyercol kinase modulating compounds | |
| EP4359413A1 (en) | Diacylglyercol kinase modulating compounds | |
| JP2015504067A5 (https=) | ||
| JP2014532768A5 (https=) | ||
| ES2362637T3 (es) | Combinaciones antitumorales que contienen un agente inhibidor de vegf y de irinotecan. | |
| JP2015500223A5 (https=) | ||
| JP2013504536A5 (https=) | ||
| JP2013518036A5 (https=) | ||
| JP2019533682A (ja) | 抗ｃｄ１９抗体とｂｃｌ−２阻害剤との組み合わせおよびその使用 | |
| AU2020343329C1 (en) | Methods of treatment | |
| US11464805B2 (en) | CCR2+ hematopoietic stem cells mediate T cell activation in adoptive cell therapy | |
| JP5548874B2 (ja) | がん免疫抑制解除剤及びがん免疫治療用組成物 | |
| RU2015120651A (ru) | Производные имидазопиридина | |
| JP2024511057A5 (https=) | ||
| JP2024511997A5 (https=) | ||
| WO2008060535A2 (en) | Use of reversine and analogs for treatment of cancer | |
| JP4460220B2 (ja) | オリゴヌクレオチド組成物、および細胞の分化を誘導するためのオリゴヌクレオチド組成物の使用 | |
| CN119584963A (zh) | 使用bcl-2抑制剂治疗多发性骨髓瘤的方法 | |
| US20110281813A1 (en) | Method of treating c-kit positive relapsed acute myeloid leukemia | |
| US20150110864A1 (en) | Novel antitumor agent comprising combination of three agents | |
| JP2005501846A (ja) | 新規組合せ製品 | |
| HK40066948A (zh) | 治疗方法 |